HK1203498A1 - 四氫吡唑並嘧啶化合物 - Google Patents

四氫吡唑並嘧啶化合物

Info

Publication number
HK1203498A1
HK1203498A1 HK15104061.9A HK15104061A HK1203498A1 HK 1203498 A1 HK1203498 A1 HK 1203498A1 HK 15104061 A HK15104061 A HK 15104061A HK 1203498 A1 HK1203498 A1 HK 1203498A1
Authority
HK
Hong Kong
Prior art keywords
tetrahydropyrazolopyrimidine
compounds
tetrahydropyrazolopyrimidine compounds
Prior art date
Application number
HK15104061.9A
Other languages
English (en)
Inventor
Roch Boivin
Eric Carlson
Atsushi Endo
Hans Hansen
Sally Ishizaka
Matthew Mackey
Sridhar Narayan
Takashi Satoh
Shawn Schiller
Lynn D Hawkins
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of HK1203498A1 publication Critical patent/HK1203498A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15104061.9A 2012-05-31 2015-04-27 四氫吡唑並嘧啶化合物 HK1203498A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654023P 2012-05-31 2012-05-31
PCT/US2013/043679 WO2013181579A2 (en) 2012-05-31 2013-05-31 Tetrahydropyrazolopyrimidine compounds

Publications (1)

Publication Number Publication Date
HK1203498A1 true HK1203498A1 (zh) 2015-10-30

Family

ID=48626649

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104061.9A HK1203498A1 (zh) 2012-05-31 2015-04-27 四氫吡唑並嘧啶化合物

Country Status (34)

Country Link
US (5) US9126999B2 (zh)
EP (1) EP2855476B1 (zh)
JP (2) JP6285918B2 (zh)
KR (2) KR102268155B1 (zh)
CN (2) CN104507939B (zh)
AR (1) AR091236A1 (zh)
AU (2) AU2013267204B8 (zh)
BR (1) BR112014030060B1 (zh)
CA (1) CA2874445C (zh)
CL (1) CL2014003278A1 (zh)
CY (1) CY1122692T1 (zh)
DK (1) DK2855476T3 (zh)
ES (1) ES2709119T3 (zh)
HK (1) HK1203498A1 (zh)
HR (1) HRP20181889T1 (zh)
HU (1) HUE040562T2 (zh)
IL (2) IL268013B2 (zh)
JO (1) JO3407B1 (zh)
LT (1) LT2855476T (zh)
MX (1) MX368455B (zh)
MY (1) MY172926A (zh)
NZ (1) NZ703459A (zh)
PE (2) PE20150220A1 (zh)
PH (2) PH12014502660B1 (zh)
PL (1) PL2855476T3 (zh)
PT (1) PT2855476T (zh)
RS (1) RS57977B1 (zh)
RU (2) RU2733959C2 (zh)
SG (1) SG11201407890VA (zh)
SI (1) SI2855476T1 (zh)
TW (1) TWI572606B (zh)
UA (1) UA113440C2 (zh)
WO (1) WO2013181579A2 (zh)
ZA (1) ZA201409273B (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
RU2671496C2 (ru) 2013-10-14 2018-11-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные 5-пиперидин-8-цианохинолина
BR112016008359B1 (pt) 2013-10-14 2022-07-19 Eisai R&D Management Co., Ltd Compostos de quinolina seletivamente substituídos, composição farmacêutica compreendendo os ditos compostos e usos dos mesmos para tratar lúpus eritematoso sistêmico, lúpus cutâneo, lúpus neuropsiquiátrico ou lúpus
CA2933466A1 (en) * 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
AU2015238298B2 (en) * 2014-03-27 2019-04-18 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
TR201909606T4 (tr) 2014-07-31 2019-07-22 Basf Se Pi̇razollari hazirlamak i̇çi̇n i̇şlem
US9938100B2 (en) 2014-12-30 2018-04-10 Kodak Alaris Inc. System and method for metallic object detection in a media transport system
KR20230145498A (ko) 2015-05-11 2023-10-17 바스프 에스이 4-아미노-피리다진의 제조 방법
AU2015401326B2 (en) * 2015-07-03 2018-07-26 China Agricultural University Benzylhydrazone compounds and preparation method and application thereof
PT3411360T (pt) * 2016-02-02 2020-06-01 Basf Se Processo catalítico de hidrogenação para preparação de pirazóis
CN107174585A (zh) * 2016-03-10 2017-09-19 兰州大学 可用作雄激素受体拮抗剂的吡啶并咪唑类化合物的新用途
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CA3031675A1 (en) * 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
US20210371386A1 (en) * 2016-08-02 2021-12-02 Solvay Sa Manufacture of hydrazinyl compounds useful in the manufacture of pyrazole carboxylic acid and derivatives, hydrazinyl compounds and their use
KR102519535B1 (ko) * 2016-09-09 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 피리딜 치환된 인돌 화합물
SI3510033T1 (sl) * 2016-09-09 2022-04-29 Novartis Ag Spojine in sestavki kot zaviralci endosomskih toličnih receptorjev
CN110177793B (zh) * 2017-05-18 2021-12-21 江苏恒瑞医药股份有限公司 杂芳基并吡唑类衍生物、其制备方法及其在医药上的应用
JP7104775B2 (ja) 2017-08-04 2022-07-21 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ７／８／９の阻害剤として有用な置換インドール化合物
KR102688509B1 (ko) 2017-08-04 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
EP3710440B1 (en) 2017-11-14 2023-04-05 Bristol-Myers Squibb Company Substituted indole compounds
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
KR20200100687A (ko) * 2017-12-15 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 에테르 화합물
MX2020006168A (es) 2017-12-18 2020-08-13 Bristol Myers Squibb Co Compuestos de 4-azaindol.
KR20200101956A (ko) * 2017-12-19 2020-08-28 브리스톨-마이어스 스큅 컴퍼니 6-아자인돌 화합물
JP7291145B2 (ja) 2017-12-19 2023-06-14 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有効な置換されたインドール化合物
US11420973B2 (en) * 2017-12-19 2022-08-23 Bristol-Myers Squibb Company Amide substituted indole compounds useful as TLR inhibitors
ES2904773T3 (es) 2017-12-20 2022-04-06 Bristol Myers Squibb Co Compuestos de diazaindol
KR20200101400A (ko) 2017-12-20 2020-08-27 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
EA202091480A1 (ru) 2017-12-20 2020-11-06 Бристол-Маерс Сквибб Компани Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
JP2021506879A (ja) * 2017-12-22 2021-02-22 ソルヴェイ（ソシエテ アノニム） ピラゾールカルボン酸誘導体及びその前駆体の製造のための方法
CN111432818A (zh) 2017-12-22 2020-07-17 诺华股份有限公司 用于治疗神经精神性系统性红斑狼疮的吡唑并哌啶衍生物和吡唑并嘧啶衍生物
JP7312745B2 (ja) * 2018-06-07 2023-07-21 第一三共株式会社 アゼチジン誘導体及びそのプロドラッグ
WO2020048596A1 (en) * 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Novel pyrazolopyridine compounds for the treatment of autoimmune disease
EP3870589B1 (en) 2018-10-24 2023-09-06 Bristol-Myers Squibb Company Substituted indole dimer compounds
JP2022506790A (ja) * 2018-11-09 2022-01-17 エフ．ホフマン－ラ ロシュ アーゲー 全身性エリテマトーデスを処置するためのＴＬＲ７～９アンタゴニストとしての、５－［６－［［３－（４，５，６，７－テトラヒドロピラゾロ［４，３－ｃ］ピリジン－１－イル）アゼチジン－１－イル］メチル］モルホリン－４－イル］キノリン－８－カルボニトリル誘導体及び類似化合物
BR112021015012A2 (pt) * 2019-02-07 2021-10-05 Beigene, Ltd. Compostos, composição farmacêutica, método de modulação de tlr7 e método de tratamento de uma doença ou distúrbio em um paciente
US20220289752A1 (en) * 2019-08-02 2022-09-15 Beigene, Ltd. Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives used as tlr8 agonists
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
WO2021112251A1 (ja) * 2019-12-06 2021-06-10 第一三共株式会社 アゼチジンスルホンアミド化合物
WO2022221642A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Thienopyrrole compounds
JP2024533374A (ja) 2021-09-10 2024-09-12 ギリアード サイエンシーズ， インコーポレイテッド チエノピロール化合物

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3116230B2 (ja) 1989-02-15 2000-12-11 武田薬品工業株式会社 三環式縮合ピリミジン誘導体
JPH04133055A (ja) 1990-09-25 1992-05-07 Konica Corp 色再現性の改良されたハロゲン化銀カラー写真感光材料
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
FR2733749B1 (fr) 1995-05-05 1997-06-13 Oreal Compositions pour la teinture des fibres keratiniques contenant des diamino pyrazoles, procede de teinture, nouveaux diamino pyrazoles et leur procede de preparation
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US6472416B1 (en) 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
EE200300192A (et) 2000-12-06 2003-08-15 Aventis Pharma Deutschland Gmbh Guanidiini ja amidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline preparaatning eelravim
NZ528639A (en) 2001-03-14 2005-07-29 Gruenenthal Chemie Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
CA2483075A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
DE10221100C1 (de) 2002-05-03 2003-06-05 Neuhaus Elektronik Gmbh Elektrisch leitfähige Dichtung sowie Verfahren und Vorrichtung zu deren Herstellung
JP2003327860A (ja) 2002-05-09 2003-11-19 Konica Minolta Holdings Inc 着色組成物、着色微粒子分散物、インクジェット用インク、インクジェット記録方法
PT1534707E (pt) 2002-06-19 2007-12-19 Janssen Pharmaceutica Nv Derivados de 2,4-di-hidro-pirrolo(3,4-b)-quinolin-9-ona substituídos, úteis como inibidores da fosfodiesterase
JP4133055B2 (ja) 2002-07-11 2008-08-13 株式会社イトーキ 移載機構を備えた自動倉庫
CN1771231B (zh) * 2002-08-26 2011-05-25 武田药品工业株式会社 钙受体调节性化合物及其用途
ES2635838T3 (es) 2002-08-26 2017-10-05 Takeda Pharmaceutical Company Limited Compuesto modulador de receptores de calcio y su uso
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
JP2006525366A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環式カルボン酸置換基
MXPA05011523A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas.
WO2004111193A2 (en) 2003-06-12 2004-12-23 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
AU2004253579B2 (en) 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
FR2865208B1 (fr) 2004-01-16 2009-01-16 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
US7279232B2 (en) 2004-01-26 2007-10-09 Universal Display Corporation Electroluminescent stability
US20080004263A1 (en) 2004-03-04 2008-01-03 Santora Vincent J Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof
JP2007536238A (ja) 2004-05-04 2007-12-13 アカディア ファーマシューティカルズ，インコーポレーテッド エストロゲン受容体で活性を持つ化合物
US7825265B2 (en) 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
WO2006044405A1 (en) 2004-10-12 2006-04-27 Decode Genetics, Inc. Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
WO2006055708A2 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids for the treatment of diabetes
JPWO2006057448A1 (ja) 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体
JP2008528510A (ja) 2005-01-20 2008-07-31 サートリス ファーマシューティカルズ， インコーポレイテッド 紅潮および／または薬物誘発性体重増加を処置するためのサーチュイン活性化化合物の使用
WO2006105440A2 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006129583A1 (ja) 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. ピラゾロン誘導体
JPWO2006129587A1 (ja) 2005-05-30 2009-01-08 株式会社ジーンケア研究所 ピラゾロン誘導体を含有する医薬組成物
JP2008546643A (ja) 2005-06-06 2008-12-25 スミスクライン ビーチャム コーポレーション ４−置換アリールアミン誘導体および医薬組成物におけるその使用
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
AU2006285599A1 (en) 2005-09-01 2007-03-08 Astellas Pharma Inc. Pyridazinone derivatives used for the treatment of pain
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
WO2007087283A2 (en) 2006-01-23 2007-08-02 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
EP1992348A4 (en) 2006-03-08 2009-09-23 Takeda Pharmaceutical PHARMACEUTICAL COMBINATION
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
JP2009538309A (ja) 2006-05-23 2009-11-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
US7851495B2 (en) 2006-05-23 2010-12-14 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
CA2654927A1 (en) 2006-06-09 2007-12-21 Icos Corporation Substituted phenyl acetic acids as dp-2 antagonists
MX2009000310A (es) 2006-07-14 2009-01-26 Novartis Ag Derivados de pirimidina como inhibidores de alk-5.
ATE488520T1 (de) 2006-08-04 2010-12-15 Merz Pharma Gmbh & Co Kgaa Pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
WO2008033894A2 (en) 2006-09-14 2008-03-20 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
CA2669917A1 (en) 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2677096A1 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated Kinase inhibitors
US8183276B2 (en) 2007-02-08 2012-05-22 Christian Fischer Therapeutic agents
EP2009002A1 (en) 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
WO2009035671A1 (en) 2007-09-12 2009-03-19 Janssen Pharmaceutica N.V. Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine h4 receptor
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
JP2011503179A (ja) * 2007-11-15 2011-01-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 エナンチオマー濃縮されたイミダゾアゼピノン化合物
CN101925383A (zh) * 2007-12-11 2010-12-22 赛特帕斯凡德株式会社 甲酰胺化合物及其作为趋化因子受体激动剂的应用
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
US20120010177A1 (en) 2008-02-20 2012-01-12 The Wistar Institute / North Carolina State University MicroRNA Modulators and Method for Identifying And Using The Same
WO2010051048A1 (en) 2008-02-20 2010-05-06 The Wistar Institute Microrna modulators and method for identifying and using the same
WO2009111207A1 (en) 2008-03-04 2009-09-11 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
WO2009148961A2 (en) 2008-05-29 2009-12-10 Wisconsin Alumni Research Foundation Drugs to prevent hpv infection
US20110144056A1 (en) 2008-06-11 2011-06-16 Lin Linus S Pyrazole derivatives useful as inhibitors of faah
US8455528B2 (en) 2008-06-11 2013-06-04 Merck Sharp & Dohme Corp. Imidazole derivatives useful as inhibitors of FAAH
WO2009153720A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
JP2011524894A (ja) 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
US8263642B2 (en) 2008-06-25 2012-09-11 Vanderbilt University Antimicrobial compounds and methods of use thereof
ES2462403T3 (es) 2008-06-25 2014-05-22 Bristol-Myers Squibb Company Diceto azolopiperidinas y azolopiperazinas como agentes anti-VIH
EP2313408B1 (en) 2008-06-25 2012-07-11 Bristol-Myers Squibb Company Diketopiperidine derivatives as hiv attachment inhibitors
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
KR20110038159A (ko) 2008-07-28 2011-04-13 길리애드 사이언시즈, 인코포레이티드 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
US8673941B2 (en) 2008-08-04 2014-03-18 Merck Sharp & Dohme Corp. Oxazole derivatives useful as inhibitors of FAAH
US20110251172A1 (en) 2008-08-13 2011-10-13 Rivkin Alexey A Purine derivatives for treatment of alzheimer's disease
BRPI0917936A2 (pt) 2008-08-25 2017-07-11 Irm Llc Moduladores de via hedgehog
ES2710701T3 (es) 2008-09-24 2019-04-26 Basf Se Compuestos de pirazol para el control de plagas de invertebrados
WO2010096115A1 (en) * 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
US20100120778A1 (en) 2008-11-07 2010-05-13 Wyeth Quinoxaline-based lxr modulators
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
JP5630868B2 (ja) 2009-01-19 2014-11-26 第一三共株式会社 ヘテロ原子を有する環状化合物
EP3626240A1 (en) 2009-03-02 2020-03-25 StemSynergy Therapeutics, Inc. Process of preparation of a n-aryl benzyl sulfonamide substituted with an amido group
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2010141696A1 (en) 2009-06-04 2010-12-09 Dara Biosciences, Inc. Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
UY33001A (es) 2009-11-06 2011-05-31 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
FR2953837B1 (fr) 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
US20120316176A1 (en) 2009-12-22 2012-12-13 Deen Tulshian DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF
EP2523664A4 (en) 2010-01-13 2013-06-26 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
JP2013518110A (ja) 2010-01-28 2013-05-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛および他の適応症の治療用の医薬組成物
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
JP5871897B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジルトリアゾール
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター
EP2371219A1 (en) 2010-04-01 2011-10-05 Basf Se Herbicidal acylhydrazides
EP3409276B1 (en) 2010-04-05 2020-12-30 Fosun Orinove Pharmatech, Inc. Ire-1a inhibitors
AU2011242961B2 (en) 2010-04-22 2015-09-24 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of FAAH
WO2011133727A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
EP2401915A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
CN102048738A (zh) 2010-12-08 2011-05-11 辽宁利锋科技开发有限公司 含有环嘧耐平药用复合物的药物组合物制剂
KR102136768B1 (ko) 2011-07-29 2020-07-23 카리오팜 쎄라퓨틱스, 인코포레이티드 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
UA117902C2 (uk) 2011-07-29 2018-10-25 Каріофарм Терапеутікс, Інк. Модулятори ядерного транспорту та їхнє застосування
JP2013159564A (ja) * 2012-02-02 2013-08-19 Kowa Co ピラゾロピリミジン−７−アミン誘導体を有効成分とするｔｌｒ９阻害剤
AU2013221873B2 (en) 2012-02-13 2016-11-17 Bristol-Myers Squibb Company Enediyne compounds, conjugates thereof, and uses and methods therefor
EA201791271A1 (ru) 2012-05-31 2018-01-31 Фенекс Фармасьютикалз Аг ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين

Also Published As

Publication number Publication date
CA2874445A1 (en) 2013-12-05
EP2855476B1 (en) 2018-09-05
CN104507939A (zh) 2015-04-08
PH12019500522A1 (en) 2020-11-04
RU2014154397A (ru) 2016-07-27
CA2874445C (en) 2022-06-21
AU2013267204A1 (en) 2015-01-29
MX368455B (es) 2019-10-03
SG11201407890VA (en) 2014-12-30
US10640500B2 (en) 2020-05-05
KR102268155B1 (ko) 2021-06-24
HUE040562T2 (hu) 2019-03-28
RU2677291C2 (ru) 2019-01-16
JP6619829B2 (ja) 2019-12-11
JP6285918B2 (ja) 2018-02-28
CN107344941B (zh) 2020-04-21
ES2709119T3 (es) 2019-04-15
AU2017204586B2 (en) 2018-11-08
US9126999B2 (en) 2015-09-08
PE20150220A1 (es) 2015-02-14
IL268013B1 (en) 2024-01-01
IL268013A (en) 2019-09-26
LT2855476T (lt) 2019-01-10
UA113440C2 (xx) 2017-01-25
BR112014030060A2 (pt) 2017-09-12
US11130758B2 (en) 2021-09-28
US20180273532A1 (en) 2018-09-27
CN104507939B (zh) 2017-07-25
AU2013267204B2 (en) 2017-04-06
MY172926A (en) 2019-12-14
WO2013181579A2 (en) 2013-12-05
BR112014030060B1 (pt) 2022-05-31
IL235986B (en) 2019-11-28
US20160339032A1 (en) 2016-11-24
RU2018146532A (ru) 2019-01-31
RU2733959C2 (ru) 2020-10-08
US9446046B2 (en) 2016-09-20
JP2015523981A (ja) 2015-08-20
CY1122692T1 (el) 2020-07-31
RS57977B1 (sr) 2019-01-31
CN107344941A (zh) 2017-11-14
US20130324547A1 (en) 2013-12-05
ZA201409273B (en) 2016-05-25
EP2855476A2 (en) 2015-04-08
IL235986A0 (en) 2015-02-01
AU2013267204B8 (en) 2017-04-13
KR20210076210A (ko) 2021-06-23
MX2014014497A (es) 2015-06-02
KR102403007B1 (ko) 2022-05-31
JO3407B1 (ar) 2019-10-20
PL2855476T3 (pl) 2019-02-28
US20160030430A1 (en) 2016-02-04
NZ703459A (en) 2016-09-30
TWI572606B (zh) 2017-03-01
WO2013181579A3 (en) 2014-03-27
AU2017204586A1 (en) 2017-07-27
JP2018087221A (ja) 2018-06-07
PH12014502660A1 (en) 2015-01-21
RU2018146532A3 (zh) 2019-06-21
TW201402575A (zh) 2014-01-16
AR091236A1 (es) 2015-01-21
HRP20181889T1 (hr) 2019-01-11
KR20150016366A (ko) 2015-02-11
US9850242B2 (en) 2017-12-26
PT2855476T (pt) 2018-12-03
PE20190973A1 (es) 2019-07-09
DK2855476T3 (en) 2018-12-17
SI2855476T1 (sl) 2018-12-31
CL2014003278A1 (es) 2015-06-12
AU2013267204A8 (en) 2017-04-13
PH12014502660B1 (en) 2015-01-21
IL268013B2 (en) 2024-05-01
US20200347050A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
IL268013A (en) Tetrahydropyrazolopyrimidine compounds
HK1245780B (zh) 咪唑並吡咯烷酮化合物
IL237341A0 (en) Compounds that promote neurogenesis
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2887803A4 (en) PRO-NEUROGENIC COMPOUNDS
HK1206726A1 (zh) 咪唑並三嗪酮化合物
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
PL2836495T3 (pl) Związki tetrahydropirolotiazynowe
GB201209096D0 (en) Compounds
HK1206356A1 (zh) -取代的氰基吡唑化合物
GB201219820D0 (en) Compounds
GB201217310D0 (en) Compounds
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218774D0 (en) Compounds
GB201218776D0 (en) Compounds
GB201218758D0 (en) Compounds
GB201218018D0 (en) Compounds
GB201217290D0 (en) Compounds
GB201217312D0 (en) Compounds